North China Pharmaceutical Group Corporation Report issue

For profit Phase 3
Founded: Shijiazhuang China (1953)
Status: No NME R&D (1953)

Organization Overview

First Clinical Trial
2008
NCT01451749
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

North-China Pharmaceutical Company, China | North China Pharmaceutical Group Corporation

Active Ingredients

Drugs in Phase 3 Trials (3)

donepezil (aricept) (1 trial)

shenwu (1 trial)

sirolimus (rapamune) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Disease (Phase 2)

Bronchitis (Phase 2)

Cognitive Dysfunction (Phase 3)

Lupus Erythematosus, Systemic (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 3